Patents by Inventor Catherine J. Trumpower
Catherine J. Trumpower has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160367603Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: September 1, 2016Publication date: December 22, 2016Applicant: Noveome Biotherapeutics, Inc.Inventors: Richard A Banas, Catherine J Trumpower
-
Patent number: 9173908Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: February 5, 2015Date of Patent: November 3, 2015Assignee: STEMNION, INC.Inventors: Richard A. Banas, Catherine J. Trumpower, Vivienne S. Marshall
-
Patent number: 9173927Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: August 1, 2014Date of Patent: November 3, 2015Assignee: STEMNION, INC.Inventors: Charlotte A Emig, Catherine J Trumpower, George L Sing
-
Publication number: 20150306149Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: July 1, 2015Publication date: October 29, 2015Applicant: STEMNION, INC.Inventors: Richard A. Banas, Catherine J. Trumpower
-
Patent number: 9138443Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: July 16, 2013Date of Patent: September 22, 2015Assignee: STEMNION, INC.Inventors: Richard A Banas, Vivienne S Marshall, Catherine J Trumpower
-
Publication number: 20150147358Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: February 5, 2015Publication date: May 28, 2015Applicant: Stemnion, Inc.Inventors: Richard A. Banas, Catherine J. Trumpower, Vivienne S. Marshall
-
Publication number: 20150050251Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: ApplicationFiled: October 23, 2014Publication date: February 19, 2015Inventors: Catherine J Trumpower, Charlotte A. Emig
-
Publication number: 20150025007Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: ApplicationFiled: August 1, 2014Publication date: January 22, 2015Inventors: Charlotte A. Emig, Catherine J. Trumpower, George L. Sing
-
Patent number: 8871198Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: GrantFiled: March 14, 2007Date of Patent: October 28, 2014Assignee: Stemnion, Inc.Inventors: Charlotte A Emig, Catherine J Trumpower, Vivienne S Marshall
-
Patent number: 8822415Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: July 19, 2013Date of Patent: September 2, 2014Assignee: Stemnion, Inc.Inventors: Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Patent number: 8796025Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: GrantFiled: May 8, 2012Date of Patent: August 5, 2014Assignee: Stemnion, Inc.Inventors: Charlotte A Emig, Catherine J Trumpower, Vivienne S Marshall
-
Patent number: 8647617Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: May 30, 2012Date of Patent: February 11, 2014Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Richard A. Banas, Catherine J. Trumpower
-
Publication number: 20130302289Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: July 16, 2013Publication date: November 14, 2013Inventors: Richard A. Banas, Vivienne S. Marshall, Catherine J. Trumpower
-
Publication number: 20130302307Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: ApplicationFiled: July 19, 2013Publication date: November 14, 2013Inventors: Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Publication number: 20130251675Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: February 23, 2013Publication date: September 26, 2013Applicant: STEMNION, INC.Inventors: Richard A Banas, Catherine J. Trumpower
-
Patent number: 8530418Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: October 17, 2012Date of Patent: September 10, 2013Assignee: Stemnion, Inc.Inventors: Vivienne S Marshall, Catherine J Trumpower, Charlotte Emig
-
Patent number: 8506949Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: May 30, 2012Date of Patent: August 13, 2013Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Richard A. Banas, Catherine J. Trumpower
-
Publication number: 20130115197Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: ApplicationFiled: October 3, 2012Publication date: May 9, 2013Applicant: STEMNION, INC.Inventors: Charlotte Emig, Catherine J. Trumpower, Vivienne S. Marshall
-
Publication number: 20130071364Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: ApplicationFiled: October 3, 2012Publication date: March 21, 2013Applicant: STEMNION, INC.Inventors: Charlotte A. Smith, Catherine J. Trumpower, Vivienne S. Marshall, Richard A. Banas
-
Publication number: 20130071363Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: ApplicationFiled: October 3, 2012Publication date: March 21, 2013Applicant: STEMNION, INC.Inventors: Charlotte A. Smith, Catherine J. Trumpower, Vivienne S. Marshall